

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4137194

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
SUNOVION CNS DEVELOPMENT CANADA ULC		10/21/2016
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	SUNOVION PHARMACEUTICALS INC.	
<b>Street Address:</b>	84 WATERFORD DRIVE	
<b>City:</b>	MARLBOROUGH	
<b>State/Country:</b>	MASSACHUSETTS	
<b>Postal Code:</b>	01752	
<b>PROPERTY NUMBERS Total: 19</b>		
<b>Property Type</b>	<b>Number</b>	
Application Number:	14962806	
Application Number:	14963835	
Application Number:	14963910	
Application Number:	14963971	
Application Number:	14971532	
Application Number:	15225992	
Application Number:	61186445	
Application Number:	61423858	
Application Number:	61483864	
Application Number:	62150624	
Patent Number:	8414922	
Patent Number:	8846074	
Patent Number:	9044475	
Patent Number:	9283219	
Patent Number:	9326981	
Patent Number:	9427412	
PCT Number:	US1038336	
PCT Number:	US1165665	
PCT Number:	US1628265	

**CORRESPONDENCE DATA****Fax Number:** (617)428-7045

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** (617) 428-0200**Email:** patentadministrator@clarkelbing.com**Correspondent Name:** CLARK & ELBING LLP**Address Line 1:** 101 FEDERAL STREET**Address Line 2:** 15TH FLOOR**Address Line 4:** BOSTON, MASSACHUSETTS 02110

<b>ATTORNEY DOCKET NUMBER:</b>	50671-001001
--------------------------------	--------------

<b>NAME OF SUBMITTER:</b>	KRISTINA BIEKER-BRADY, PH.D.
---------------------------	------------------------------

<b>SIGNATURE:</b>	/Kristina Bieker-Brady, Ph.D./
-------------------	--------------------------------

<b>DATE SIGNED:</b>	11/10/2016
---------------------	------------

**Total Attachments: 4**

source=262. Confirmatory Patent Assignment Worldwide#page1.tif

source=262. Confirmatory Patent Assignment Worldwide#page2.tif

source=262. Confirmatory Patent Assignment Worldwide#page3.tif

source=262. Confirmatory Patent Assignment Worldwide#page4.tif

**CONFIRMATORY ASSIGNMENT**

<b>Full Name of Assignor</b>	<b>State of Incorporation</b>	<b>Business Address</b>
Sunovion CNS Development Canada ULC	British Columbia	1600-925 West Georgia Street Vancouver, BC V6C 3L2 Canada

acknowledges the assignment, as of October 20, 2016, to:

<b>Full Name of Assignee</b>	<b>Jurisdiction of Incorporation</b>	<b>Business Address</b>
Sunovion Pharmaceuticals Inc.	Delaware	84 Waterford Drive Marlborough, MA 01752 United States of America

and to its successors and assigns (collectively hereinafter called the "ASSIGNEE"), for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, the entire right, title, and interest in, to, and deriving from all inventions the title or control of title was held by ASSIGNOR or to which ASSIGNOR had a lawful claim to hold or control title including without limitation the invention(s) disclosed in the patent application(s) set forth below throughout the world by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same including any patent application claiming priority, divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

Furthermore, we authorize and request the attorneys appointed in said patent applications to hereafter complete this assignment by inserting below the filing date and serial number of said applications when known; this assignment includes said patent applications, any and all United States and foreign patents, utility models, and design registrations granted for any of said patent inventions or improvements, and the right to claim priority based on the filing date of said applications under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further patent applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.

<b>Title of Application</b>	<b>Filing Date</b>	<b>Jurisdiction</b>	<b>Application Serial Number</b>
SUBLINGUAL APOMORPHINE	June 12, 2009	United States	61/186,445
SUBLINGUAL APOMORPHINE	June 11, 2010	United States	12/813,820
SUBLINGUAL APOMORPHINE	April 10, 2015	United States	14/684,146
SUBLINGUAL APOMORPHINE	December 9, 2015	United States	14/963,971
SUBLINGUAL APOMORPHINE	December 9, 2015	United States	14/963,835
SUBLINGUAL APOMORPHINE	December 9, 2015	United States	14/963,910
SUBLINGUAL APOMORPHINE	December 8, 2015	United States	14/962,806
SUBLINGUAL APOMORPHINE	December 16, 2015	United States	14/971,532


Title of Application	Filing Date	Jurisdiction	Application Serial Number
SUBLINGUAL APOMORPHINE	June 11, 2010	PCT	PCT/US2010/038336
SUBLINGUAL APOMORPHINE	June 11, 2010	Australia	AU2010259971
SUBLINGUAL APOMORPHINE	June 11, 2010	Canada	2,765,291
SUBLINGUAL APOMORPHINE	June 11, 2010	China	201080035644.4
SUBLINGUAL APOMORPHINE	June 11, 2010	Hong Kong	12112345.3
SUBLINGUAL APOMORPHINE	June 8, 2016	Hong Kong	16106649.4
SUBLINGUAL APOMORPHINE	June 11, 2010	European Patent Office	10786915.8
SUBLINGUAL APOMORPHINE	July 3, 2015	European Patent Office	15175258.1
SUBLINGUAL APOMORPHINE	June 11, 2010	Eurasian Patent Office	EA 201270012
SUBLINGUAL APOMORPHINE	June 11, 2010	Indonesia	W00201104774
SUBLINGUAL APOMORPHINE	June 11, 2010	Mexico	MX/a/2011/013260
SUBLINGUAL APOMORPHINE	June 11, 2010	New Zealand	597237
SUBLINGUAL APOMORPHINE	June 11, 2010	South Africa	2011/09208
SUBLINGUAL FILMS	December 16, 2010	United States	61/423,858
SUBLINGUAL FILMS	May 9, 2011	United States	61/483,864
SUBLINGUAL FILMS	April 12, 2012	United States	13/445,656
SUBLINGUAL FILMS	April 8, 2013	United States	13/858,638
SUBLINGUAL FILMS	September 5, 2014	United States	14/478,975
SUBLINGUAL FILMS	February 3, 2016	United States	15/014,655
SUBLINGUAL FILMS	August 2, 2016	United States	15/225,992
SUBLINGUAL FILMS	December 16, 2011	PCT	PCT/US2011/065665
SUBLINGUAL FILMS	December 16, 2011	Australia	AU2011343429
SUBLINGUAL FILMS	December 16, 2011	Canada	2,821,756
SUBLINGUAL FILMS	December 16, 2011	China	201180067683.7
SUBLINGUAL FILMS	December 16, 2011	Hong Kong	14106298.0
SUBLINGUAL FILMS	December 16, 2011	European Patent Office	11848299.1
SUBLINGUAL FILMS	December 16, 2011	Eurasian Patent Office	EA201390855
SUBLINGUAL FILMS	December 16, 2011	Indonesia	W00201303084
SUBLINGUAL FILMS	December 16, 2011	Mexico	MX/a/2013/006911
SUBLINGUAL FILMS	December 16, 2011	New Zealand	NZ 612686
SUBLINGUAL FILMS	December 16, 2011	South Africa	ZA 2013/04740

<b>Title of Application</b>	<b>Filing Date</b>	<b>Jurisdiction</b>	<b>Application Serial Number</b>
METHODS OF TREATING PARKINSON'S DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA	April 21, 2015	United States	62/150,624
METHODS OF TREATING PARKINSON'S DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA	April 19, 2016	PCT	PCT/US2016/028265

This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

**ASSIGNOR**



  
For: Sunovion CNS Development Canada ULC


  
Date

Representative Name: Gregory M. Bokar


Representative Title: Director


**Witness:**

  
Signature  
  
Printed name

  
Date

**ASSIGNEE**



  
For: Sunovion Pharmaceuticals Inc.


  
Date

Representative Name: Gregory M. Bokar

Representative Title: Senior Vice President, Legal Affairs and Corporate Secretary

**Witness:**

  
Signature  
  
Printed name

  
Date